Partial
Partially Aligned
Patient Risk:
Low
Summary
Some statements about the approved indication (partial-onset seizures; patients ≥1 month) and that brivaracetam is the active ingredient are consistent with the provided label excerpt. However, multiple brand-name/marketing claims are not supported by the provided prescribing-information sections, so overall alignment is partial.
Category Scores
Accurate Statements
The provided label excerpt supports that brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Section 1 INDICATIONS & USAGE: “Brivaracetam oral solution is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.”
The brand name can differ while the active ingredient is brivaracetam (i.e., brivaracetam is the generic/active ingredient).
Section 11 DESCRIPTION: “Brivaracetam oral solution contains 10 mg of brivaracetam per mL.”
Unsupported Statements
Brivaracetam is marketed under multiple brand names depending on the country.
Not supported by the provided label excerpts (Sections 1 and 11).
Commonly used brand names for brivaracetam include Briviact and Briveracetam (or versions of that name) in some markets.
Not supported by the provided label excerpts.
Briviact is one of the most widely recognized brivaracetam brands.
Not supported by the provided label excerpts.
Briviact is used in several countries for the prescription anti-seizure medicine.
Not supported by the provided label excerpts.
Brivaracetam may appear under other brand labels besides Briviact, often tied to local distributors or country-specific approvals.
Not supported by the provided label excerpts.
The active ingredient on the label should list brivaracetam as the generic name even if the brand name differs by country or manufacturer.
Not supported by the provided label excerpts; also framed as a directive/expectation not present in the excerpts.
The brand name changes, but the active ingredient is the same: brivaracetam.
Partially supported (active ingredient brivaracetam is present in the product), but the specific claim about label brand changing by country/manufacturer is not supported by the provided excerpts.
Contradictions
Important Omissions
Any additional safety, contraindications, boxed warnings, dosing/administration details, or monitoring recommendations that would be necessary for a complete label alignment assessment were not provided for evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly label-supported clinical claim in the provided excerpts is the indication for partial-onset seizures in patients ≥1 month. The remaining statements relate to brand-name marketing and are unsupported by the provided label sections; they do not introduce dosing/safety contradictions within the evaluated scope.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple brand-name/market-availability claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is present in the provided label sections (e.g., indication and that the product contains brivaracetam). Avoid country/brand-distribution assertions unless supported by the specific prescribing information provided.